IL2 and systemic lupus erythematosus: Clinical evidence demonstrates that low-dose recombinant human IL-2 therapy selectively expands Treg populations while reducing pathogenic Th17 and Tfh cells, correlating with significant attenuation of SLE disease activity (He et al., 2016).